Symptomatic increase in intracranial pressure following pancreatic enzyme replacement therapy for cystic fibrosis.
A newly diagnosed 5-month-old infant with cystic fibrosis (CF) developed signs and symptoms of increased intracranial pressure (ICP) within days of starting pancreatic enzyme replacement therapy. Symptoms promptly resolved on two occasions after stopping enzyme replacement. At 10 months of age, enzyme replacement was well tolerated.
Nasr
S Z
SZ
University of Michigan Medical Center, Department of Pediatrics, Ann Arbor 48109-0718, USA.
Schaffert
D
D
D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects; D006801:Humans; D007223:Infant; D008297:Male; D010194:Pancreatin / Q000008:administration & dosage* / Q000009:adverse effects; D011559:Pseudotumor Cerebri / Q000139:chemically induced*
D005765:Gastrointestinal Agents; D010194:Pancreatin